Inês T Simões, Fernando Aranda, Sergi Casadó-Llombart, María Velasco-de Andrés, Cristina Català, Pilar Álvarez, Marta Consuegra-Fernández, Marc Orta-Mascaró, Ramón Merino, Jesús Merino, José Alberola-Ila, Gloria González-Aseguinolaza, Esther Carreras, Vanesa Martínez, Francisco Lozano
BACKGROUND: CD6 is a lymphocyte surface co-receptor physically associated with the T-cell receptor (TCR)/CD3 complex at the center of the immunological synapse. There, CD6 assists in cell-to-cell contact stabilization and modulation of activation/differentiation events through interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), its main reported ligand. While accumulating evidence is attracting new interest on targeting CD6 for therapeutic purposes in autoimmune disorders, little is known on its potential in cancer...
March 2020: Journal for Immunotherapy of Cancer